- GSK shares rise as $2.5B cost-cutting plan unveiledAs GSK records $2.4 billion in impairment charges for the second quarter, the U.K. pharma has announced a sweeping restructure designed to save about the same amount of money over the next few years.
- FDA reminds investors about the risks of advisory panelsTwo days, two similar briefing documents and two companies with diving share prices. The FDA this week laid out its concerns with clinical data from both Capricor Therapeutics and